Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Revitol Cellulite Cream

Trinam(R) Phase III Study Enrols First Patient
Ark Therapeutics Group plc ("Ark" or the "Company") announces that the first patient has been enrolled into the US Phase III study for Trinam®. Trinam® is Ark"s novel gene-based medicine to prevent blood vessels blocking in kidney dialysis patients who have undergone vascular access graft surgery. The product is an adenovirus-mediated VEGF D gene delivered with a novel biodegradeable local delivery device (EG001). Don't forget to buy zoloft online no prescription.

Fertility Prediction Kit Ovu-Trac(R) By OvumOptics Harnesses The Testing Power Of Saliva Testing
Saliva sample testing is fast becoming the diagnostic data collector of choice in a variety of medical testing. Over the past two years, American scientists are turning more to the accuracy of results in saliva sample tests, more than traditional blood and urine tests. Ovu-Trac® is at the leading edge of this scientific knowledge with its ovulation test and predictor kit. These fertility test kits can help women who are trying to conceive a child determine when they are ovulating.

generic viagra online


News of the day
Study Suggests Preseason Shoulder Strength May Determine Injury Severity For Baseball Pitchers
Athletic injuries can derail any player"s ability to compete, but for a baseball pitcher his shoulder strength and control is critical. A new study to be presented at the American Orthopaedic Society for Sports Medicine"s (AOSSM) Annual Meeting in Keystone, Colorado, suggests that testing a pitcher"s shoulder strength through a series of exercises during the preseason may help create a focused strength training program to prevent serious injury during the season.
Nutrition

UCLA Study Discovers Enzyme That Controls 'Bad' Cholesterol

BACKGROUND: Low-density lipoprotein (LDL) is the so-called "bad cholesterol" often linked to medical problems like heart disease and clogged arteries. Cells in the liver produce a specific receptor that sticks to LDL and removes it from the blood, lowering cholesterol levels. Statin drugs also reduce LDL cholesterol levels by boosting cells" production of the receptor. FINDINGS: Using a mouse model, UCLA scientists discovered a new mechanism that controls cells" production of LDL receptor. The team identified an enzyme called Idol that destroys the receptor, permitting more LDL cholesterol to circulate in the blood. In blocking Idol"s activity, the researchers triggered cells to make more receptor and absorb more cholesterol from the body. "We only know of three pathways that regulate the LDL receptor. The first two are already targeted by existing drugs," explained Dr. Peter Tontonoz, professor of pathology and laboratory medicine at the David Geffen School of Medicine at UCLA and an investigator at the Howard Hughes Medical Institute. "Idol is the first mechanism discovered in several years that may lead to a new medication designed to control cholesterol levels." IMPACT: The findings suggest that development of a drug that interferes with Idol"s activity could influence cholesterol metabolism and lower levels of bad cholesterol. Doctors could prescribe the new medication in conjunction with statin drugs, which also cut cholesterol levels by targeting a different enzyme linked to the LDL receptor. This could benefit patients that cannot tolerate statin-related side effects. AUTHORS: Tontonoz collaborated with Noam Zelcer, Cynthia Hong and Rima Boyadjian. The research was funded by the Howard Hughes Medical Institute and the National Heart, Lung and Blood Institute. Tontonoz and Zelcer have filed a patent related to the research findings. JOURNAL: The research appears in the June 11 online edition of the journal Science. Elaine Schmidt University of California - Los Angeles


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009